Lv1
89 积分 2021-07-21 加入
The use of pharmacotherapies in non-cirrhotic metabolic dysfunction-associated steatohepatitis: a UK expert consensus
4小时前
已完结
Clinical trial design, biomarkers and end points in metabolic and alcohol-related liver disease
4天前
已完结
Implementing sustainable liver health in Europe: a second EASL–Lancet Commission
6天前
已完结
The use of pharmacotherapies in non-cirrhotic metabolic dysfunction-associated steatohepatitis: a UK expert consensus
6天前
已完结
From science to public health impact: enacting the recommendations of the EASL-Lancet Commission on liver health in Europe
7天前
已完结
Epidemiology and determinants of obesity in China
11天前
已完结
CONFIDENCE INTERVALS FOR DIRECTLY STANDARDIZED RATES: A METHOD BASED ON THE GAMMA DISTRIBUTION
12天前
已完结
No Adjustments Are Needed for Multiple Comparisons
15天前
已完结
The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis
15天前
已完结
Lifespan approaches for the prevention and management of steatotic liver disease
19天前
已完结
皖公网安备34019202002308
